$5.3
0.66%
Downside
Day's Volatility :3.92%
Upside
3.28%
28.3%
Downside
52 Weeks Volatility :61.5%
Upside
46.3%
Period | Cytek Biosciences Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -11.67% | 5.1% | 0.0% |
6 Months | -25.93% | 4.9% | 0.0% |
1 Year | -22.85% | 16.6% | 0.0% |
3 Years | -77.88% | 13.2% | -22.3% |
Market Capitalization | 697.0M |
Book Value | $2.96 |
Earnings Per Share (EPS) | -0.14 |
Wall Street Target Price | 8.7 |
Profit Margin | -8.88% |
Operating Margin TTM | -18.29% |
Return On Assets TTM | -3.01% |
Return On Equity TTM | -4.32% |
Revenue TTM | 197.7M |
Revenue Per Share TTM | 1.49 |
Quarterly Revenue Growth YOY | -6.2% |
Gross Profit TTM | 101.0M |
EBITDA | -17.4M |
Diluted Eps TTM | -0.14 |
Quarterly Earnings Growth YOY | 0.66 |
EPS Estimate Current Year | -0.08 |
EPS Estimate Next Year | 0.04 |
EPS Estimate Current Quarter | -0.03 |
EPS Estimate Next Quarter | -0.01 |
What analysts predicted
Upside of 64.15%
FY19 | Y/Y Change | |
---|---|---|
Revenue | 57.9M | - |
Net Income | -16.8M | - |
Net Profit Margin | -29.07% | - |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 92.8M | ↑ 60.39% |
Net Income | 19.4M | ↓ 215.36% |
Net Profit Margin | 20.91% | ↑ 49.98% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 128.0M | ↑ 37.82% |
Net Income | 4.4M | ↓ 77.24% |
Net Profit Margin | 3.45% | ↓ 17.46% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 164.0M | ↑ 28.2% |
Net Income | 2.6M | ↓ 41.68% |
Net Profit Margin | 1.57% | ↓ 1.88% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 193.0M | ↑ 17.67% |
Net Income | -12.1M | ↓ 571.58% |
Net Profit Margin | -6.29% | ↓ 7.86% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 37.1M | ↓ 23.27% |
Net Income | -6.8M | ↓ 292.89% |
Net Profit Margin | -18.35% | ↓ 25.65% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 49.7M | ↑ 33.99% |
Net Income | -4.4M | ↓ 35.54% |
Net Profit Margin | -8.83% | ↑ 9.52% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 48.0M | ↓ 3.41% |
Net Income | -6.5M | ↑ 47.13% |
Net Profit Margin | -13.45% | ↓ 4.62% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 58.2M | ↑ 21.32% |
Net Income | 5.5M | ↓ 185.24% |
Net Profit Margin | 9.45% | ↑ 22.9% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 44.9M | ↓ 22.96% |
Net Income | -6.2M | ↓ 212.1% |
Net Profit Margin | -13.75% | ↓ 23.2% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 46.6M | ↑ 3.92% |
Net Income | -10.4M | ↑ 69.14% |
Net Profit Margin | -22.38% | ↓ 8.63% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 70.4M | - |
Total Liabilities | 112.1M | - |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 220.0M | ↑ 212.64% |
Total Liabilities | 236.0M | ↑ 110.6% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 463.7M | ↑ 110.79% |
Total Liabilities | 56.9M | ↓ 75.89% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 519.5M | ↑ 12.03% |
Total Liabilities | 93.9M | ↑ 65.08% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 497.7M | ↓ 4.2% |
Total Liabilities | 104.6M | ↑ 11.36% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 524.6M | ↑ 0.98% |
Total Liabilities | 101.1M | ↑ 7.65% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 525.1M | ↑ 0.09% |
Total Liabilities | 100.9M | ↓ 0.24% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 519.4M | ↓ 1.07% |
Total Liabilities | 103.9M | ↑ 3.0% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 497.7M | ↓ 4.19% |
Total Liabilities | 104.6M | ↑ 0.67% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 492.1M | ↓ 1.13% |
Total Liabilities | 99.5M | ↓ 4.93% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 483.7M | ↓ 1.7% |
Total Liabilities | 94.6M | ↓ 4.88% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -13.7M | - |
Investing Cash Flow | -973.0K | - |
Financing Cash Flow | 93.0K | - |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 15.2M | ↓ 210.25% |
Investing Cash Flow | -1.5M | ↑ 58.99% |
Financing Cash Flow | 122.6M | ↑ 131735.48% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 4.6M | ↓ 69.45% |
Investing Cash Flow | -21.0M | ↑ 1257.01% |
Financing Cash Flow | 213.6M | ↑ 74.18% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -12.2M | ↓ 364.17% |
Investing Cash Flow | -55.9M | ↑ 166.32% |
Financing Cash Flow | 5.5M | ↓ 97.42% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 2.9M | ↓ 53.85% |
Investing Cash Flow | -168.9M | ↑ 230.71% |
Financing Cash Flow | 203.0K | ↓ 94.73% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -2.9M | ↓ 199.72% |
Investing Cash Flow | 2.8M | ↓ 101.65% |
Financing Cash Flow | 216.0K | ↑ 6.4% |
Sell
Neutral
Buy
Cytek Biosciences Inc is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Cytek Biosciences Inc | 4.13% | -25.93% | -22.85% | -77.88% | -71.75% |
![]() Stryker Corporation | 12.3% | 0.36% | 24.19% | 28.8% | 65.26% |
![]() Boston Scientific Corp. | 10.6% | 20.32% | 51.42% | 80.93% | 95.5% |
![]() Edwards Lifesciences Corp. | 9.4% | -28.78% | -12.2% | -45.23% | -7.73% |
![]() Abbott Laboratories | 3.57% | -5.84% | 13.1% | -11.32% | 35.19% |
![]() Medtronic Plc | 10.85% | 5.57% | 12.46% | -33.2% | -16.71% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Cytek Biosciences Inc | 351.5 | NA | NA | -0.08 | -0.04 | -0.03 | NA | 2.96 |
![]() Stryker Corporation | 39.84 | 39.84 | 2.64 | 12.0 | 0.19 | 0.07 | 0.01 | 51.86 |
![]() Boston Scientific Corp. | 66.34 | 66.34 | 2.01 | 2.41 | 0.09 | 0.05 | NA | 13.85 |
![]() Edwards Lifesciences Corp. | 26.3 | 26.3 | 3.2 | 2.69 | 0.22 | 0.12 | NA | 12.35 |
![]() Abbott Laboratories | 35.92 | 35.92 | 4.16 | 4.66 | 0.14 | 0.06 | 0.02 | 22.6 |
![]() Medtronic Plc | 30.16 | 30.16 | 1.66 | 5.2 | 0.08 | 0.04 | 0.03 | 37.39 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Cytek Biosciences Inc | Buy | $697.0M | -71.75% | 351.5 | -8.88% |
![]() Stryker Corporation | Buy | $136.8B | 65.26% | 39.84 | 16.12% |
![]() Boston Scientific Corp. | Buy | $120.2B | 95.5% | 66.34 | 12.0% |
![]() Edwards Lifesciences Corp. | Buy | $40.2B | -7.73% | 26.3 | 23.74% |
![]() Abbott Laboratories | Buy | $198.1B | 35.19% | 35.92 | 13.65% |
![]() Medtronic Plc | Buy | $115.3B | -16.71% | 30.16 | 12.06% |
Insights on Cytek Biosciences Inc
Revenue is up for the last 2 quarters, 44.86M → 46.61M (in $), with an average increase of 3.8% per quarter
Netprofit is down for the last 3 quarters, 5.50M → -10.43M (in $), with an average decrease of 140.6% per quarter
In the last 1 year, Boston Scientific Corp. has given 51.4% return, outperforming this stock by 74.3%
In the last 3 years, Boston Scientific Corp. has given 80.9% return, outperforming this stock by 158.8%
BlackRock Inc
Vanguard Group Inc
Brown Capital Management, LLC
Hillhouse Capital Advisors, Ltd.
State Street Corporation
New York State Common Retirement Fund
Cytek Biosciences, Inc. is a life sciences technology company engaged in the provision of cell analysis tools by leveraging novel technical approaches.
Organization | Cytek Biosciences Inc |
Employees | 645 |
CEO | Dr. Wenbin Jiang Ph.D. |
Industry | Healthcare |